Expression of Tgfβ1 and Inflammatory Markers in the 6-hydroxydopamine Mouse Model of Parkinson's Disease

被引:41
|
作者
Haas, Stefan Jean-Pierre [1 ]
Zhou, Xiaolai [2 ,3 ]
Machado, Venissa [2 ,4 ,5 ]
Wree, Andreas [1 ]
Krieglstein, Kerstin [4 ]
Spittau, Bjoern [4 ]
机构
[1] Univ Rostock, Med Ctr, Inst Anat, D-18055 Rostock, Germany
[2] Univ Freiburg, Inst Anat & Cell Biol, Dept Mol Embryol, Hugstetter Str 55, D-79106 Freiburg, Germany
[3] Cornell Univ, Weill Inst Cell & Mol Biol, Dept Mol Biol & Genet, Ithaca, NY USA
[4] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, Hugstetter Str 55, D-79106 Freiburg, Germany
[5] Univ Freiburg, Fac Biol, Hugstetter Str 55, D-79106 Freiburg, Germany
来源
关键词
6-OHDA; microglia; astrocytes; Tnfu; Tgf beta 1; GROWTH-FACTOR BETA-1; MICROGLIAL ACTIVATION; TIME-COURSE; 6-OHDA; SYSTEM; CELLS; NEURONS; NG2; MACROPHAGES; ASTROCYTES;
D O I
10.3389/fnmol.2016.00007
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkinson's disease (PD) is a neurodegenerative disorder that is characterized by loss of midbrain dopaminergic (mDA) neurons in the substantia nigra (SN). Microgliamediated neuroinflammation has been described as a common hallmark of PD and is believed to further trigger the progression of neurodegenerative events. Injections of 6-hydroxydopamine (6-OHDA) are widely used to induce degeneration of mDA neurons in rodents as an attempt to mimic PD and to study neurodegeneration, neuroinflammation as well as potential therapeutic approaches. In the present study, we addressed microglia and astroglia reactivity in the SN and the caudatoputamen (CPu) after 6-0HDA injections into the medial forebrain bundle (MFB), and further analyzed the temporal and spatial expression patterns of pro-inflammatory and anti-inflammatory markers in this mouse model of PD. We provide evidence that activated microglia as well as neurons in the lesioned SN and CPu express Transforming growth factor beta 1 (Tgf beta 1), which overlaps with the downregulation of pro-inflammatory markers Tnfu, and iNos, and upregulation of anti-inflammatory markers Yrn /and Argl. Taken together, the data presented in this study suggest an important role for Tgf beta 1 as a lesion-associated factor that might be involved in regulating microglia activation states in the 6-OHDA mouse model of PD in order to prevent degeneration of uninjured neurons by microglia-mediated release of neurotoxic factors such as Info and nitric oxide (NO).
引用
收藏
页数:14
相关论文
共 50 条
  • [41] A Guide to the Generation of a 6-Hydroxydopamine Mouse Model of Parkinson's Disease for the Study of Non-Motor Symptoms
    Masini, Debora
    Plewnia, Carina
    Bertho, Maelle
    Scalbert, Nicolas
    Caggiano, Vittorio
    Fisone, Gilberto
    BIOMEDICINES, 2021, 9 (06)
  • [42] Amphiregulin blockade decreases the levodopa-induced dyskinesia in a 6-hydroxydopamine Parkinson's disease mouse model
    Kambey, Piniel Alphayo
    Liu, Wen Ya
    Wu, Jiao
    Tang, Chuanxi
    Buberwa, Wokuheleza
    Saro, Adonira
    Nyalali, Alphonce M. K.
    Gao, Dianshuai
    CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (10) : 2925 - 2939
  • [43] Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease
    Grealish, Shane
    Mattsson, Bengt
    Draxler, Peter
    Bjorklund, Anders
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2010, 31 (12) : 2266 - 2278
  • [44] Rho Kinase Inhibition by Fasudil in the Striatal 6-Hydroxydopamine Lesion Mouse Model of Parkinson Disease
    Tatenhorst, Lars
    Toenges, Lars
    Saal, Kim-Ann
    Koch, Jan C.
    Szego, Eva M.
    Baehr, Mathias
    Lingor, Paul
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2014, 73 (08): : 770 - 779
  • [45] Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease
    Quintero, Elias Matthew
    Willis, Lauren
    Singleton, Rachel
    Harris, Naida
    Huang, Peng
    Bhat, Narayan
    Granholm, Ann-Charlotte
    BRAIN RESEARCH, 2006, 1093 : 198 - 207
  • [46] Metabolic-dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson's disease
    Casteels, Cindy
    Lauwers, Erwin
    Bormans, Guy
    Baekelandt, Veerle
    Van Laere, Koen
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (01) : 124 - 134
  • [47] Upregulation of Cysteine Protease Cathepsin X in the 6-Hydroxydopamine Model of Parkinson's Disease
    Pislar, Anja
    Tratnjek, Larisa
    Glavan, Gordana
    Zivin, Marko
    Kos, Janko
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2018, 11
  • [48] Neuroprotective effect of bromelain in 6-hydroxydopamine induced in vitro model of Parkinson's disease
    Okkay, Irmak Ferah
    Okkay, Ufuk
    Cicek, Betul
    Yilmaz, Aysegul
    Yesilyurt, Fatma
    Mendil, Ali Sefa
    Hacimuftuoglu, Ahmet
    MOLECULAR BIOLOGY REPORTS, 2021, 48 (12) : 7711 - 7717
  • [49] Paeonol Protection Against Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson's Disease
    Ghalami, Jamileh
    Mojarad, Tourandokht Baluchnejad
    Mansouri, Monireh
    Khamse, Safoura
    Roghani, Mehrdad
    BASIC AND CLINICAL NEUROSCIENCE, 2021, 12 (01) : 43 - 55
  • [50] The footfault test as a screening tool in the 6-hydroxydopamine rat model of Parkinson's disease
    Silvestrin, Roberta Bristot
    de Oliveira, Lucas Fuerstenau
    Batassini, Cristiane
    Oliveira, Alcyr
    Mello e Souza, Tadeu
    JOURNAL OF NEUROSCIENCE METHODS, 2009, 177 (02) : 317 - 321